CO5140112A1 - Compuestos de benzimidazol que son antagonistas de receptor de vitronectina - Google Patents
Compuestos de benzimidazol que son antagonistas de receptor de vitronectinaInfo
- Publication number
- CO5140112A1 CO5140112A1 CO99075257A CO99075257A CO5140112A1 CO 5140112 A1 CO5140112 A1 CO 5140112A1 CO 99075257 A CO99075257 A CO 99075257A CO 99075257 A CO99075257 A CO 99075257A CO 5140112 A1 CO5140112 A1 CO 5140112A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- heterocycloalkyl
- aryl
- arylcycloalkyl
- cycloalkylalkyl
- Prior art date
Links
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical class C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 18
- 125000003118 aryl group Chemical group 0.000 abstract 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 10
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 9
- 125000004350 aryl cycloalkyl group Chemical group 0.000 abstract 9
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 9
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 9
- 125000005843 halogen group Chemical group 0.000 abstract 9
- 125000001072 heteroaryl group Chemical group 0.000 abstract 9
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 8
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 abstract 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 102100035140 Vitronectin Human genes 0.000 abstract 1
- 108010031318 Vitronectin Proteins 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20161198A | 1998-11-30 | 1998-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5140112A1 true CO5140112A1 (es) | 2002-03-22 |
Family
ID=22746536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO99075257A CO5140112A1 (es) | 1998-11-30 | 1999-11-30 | Compuestos de benzimidazol que son antagonistas de receptor de vitronectina |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1135374B9 (enExample) |
| JP (1) | JP4480117B2 (enExample) |
| CN (1) | CN1161340C (enExample) |
| AR (1) | AR021427A1 (enExample) |
| AT (1) | ATE338751T1 (enExample) |
| AU (1) | AU1908400A (enExample) |
| CA (1) | CA2353063C (enExample) |
| CO (1) | CO5140112A1 (enExample) |
| DE (1) | DE69933135T2 (enExample) |
| ES (1) | ES2273517T3 (enExample) |
| PE (1) | PE20001427A1 (enExample) |
| WO (1) | WO2000032578A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010112408A (ko) * | 1999-04-07 | 2001-12-20 | 모리타 다카카즈 | Ｎ-치환되고-Ｎ'-치환된 우레아 유도체 및 ＴＮＦ-α 생성억제제로서의 그의 용도 |
| PL352367A1 (en) * | 1999-05-17 | 2003-08-25 | Novo Nordisk As | Glucagon antagonists/inverse agonists |
| FR2809396B1 (fr) | 2000-05-24 | 2005-10-14 | Centre Nat Rech Scient | Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation |
| US6562807B2 (en) | 2000-06-23 | 2003-05-13 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| WO2008148845A2 (en) | 2007-06-07 | 2008-12-11 | Novozymes A/S | Method of preparing a dough-based product |
| EP2595488B1 (en) | 2010-07-21 | 2019-12-04 | Novozymes A/S | Process for preparing a baked product with anti-staling amylase and peptidase |
| WO2015121210A1 (en) | 2014-02-11 | 2015-08-20 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as midh1 inhibitors |
| US9951027B2 (en) | 2014-02-11 | 2018-04-24 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as MIDH1 inhibitors |
| CN104694290A (zh) * | 2014-05-07 | 2015-06-10 | 宁波职业技术学院 | 一种洗脚皂 |
| US10138226B2 (en) | 2014-10-23 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as MIDH1 inhibitors |
| CN107108554B (zh) | 2014-10-23 | 2020-11-06 | 德国癌症研究中心 | 作为midh1抑制剂用于治疗肿瘤的1-环己基-2-苯基氨基苯并咪唑 |
| CA2988356A1 (en) | 2015-06-08 | 2016-12-15 | Bayer Pharma Aktiengesellschaft | N-menthylbenzimidazoles as midh1 inhibitors |
| CA2992364A1 (en) | 2015-07-16 | 2017-01-19 | Bayer Pharma Aktiengesellschaft | 5-hydroxyalkylbenzimidazoles as midh1 inhibitors |
| TW202146416A (zh) | 2019-12-11 | 2021-12-16 | 德商拜耳廠股份有限公司 | 吡唑并三𠯤 |
| AU2021231312A1 (en) | 2020-03-06 | 2022-08-25 | Bayer Aktiengesellschaft | Imidazotriazines acting on cancer via inhibition of CDK12 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10501222A (ja) * | 1994-05-27 | 1998-02-03 | メルク エンド カンパニー インコーポレーテッド | 破骨細胞仲介骨吸収を抑制するための化合物 |
| BR9508178A (pt) * | 1994-06-29 | 1997-11-18 | Smithkline Beecham Corp | Antagonistas de receptor de vitronectina |
-
1999
- 1999-09-29 CN CN99815842.9A patent/CN1161340C/zh not_active Expired - Fee Related
- 1999-11-29 DE DE69933135T patent/DE69933135T2/de not_active Expired - Lifetime
- 1999-11-29 CA CA002353063A patent/CA2353063C/en not_active Expired - Fee Related
- 1999-11-29 EP EP99962691A patent/EP1135374B9/en not_active Expired - Lifetime
- 1999-11-29 ES ES99962691T patent/ES2273517T3/es not_active Expired - Lifetime
- 1999-11-29 WO PCT/US1999/026023 patent/WO2000032578A1/en not_active Ceased
- 1999-11-29 JP JP2000585220A patent/JP4480117B2/ja not_active Expired - Lifetime
- 1999-11-29 AT AT99962691T patent/ATE338751T1/de not_active IP Right Cessation
- 1999-11-29 AR ARP990106061A patent/AR021427A1/es unknown
- 1999-11-29 AU AU19084/00A patent/AU1908400A/en not_active Abandoned
- 1999-11-30 CO CO99075257A patent/CO5140112A1/es unknown
- 1999-11-30 PE PE1999001198A patent/PE20001427A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000032578A8 (en) | 2002-02-07 |
| ATE338751T1 (de) | 2006-09-15 |
| WO2000032578A1 (en) | 2000-06-08 |
| PE20001427A1 (es) | 2000-12-18 |
| CA2353063C (en) | 2009-06-16 |
| ES2273517T3 (es) | 2007-05-01 |
| CA2353063A1 (en) | 2000-06-08 |
| CN1333755A (zh) | 2002-01-30 |
| AU1908400A (en) | 2000-06-19 |
| CN1161340C (zh) | 2004-08-11 |
| DE69933135D1 (de) | 2006-10-19 |
| DE69933135T2 (de) | 2007-08-09 |
| AR021427A1 (es) | 2002-07-17 |
| JP2002531441A (ja) | 2002-09-24 |
| EP1135374A1 (en) | 2001-09-26 |
| JP4480117B2 (ja) | 2010-06-16 |
| EP1135374B1 (en) | 2006-09-06 |
| EP1135374B9 (en) | 2007-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5140112A1 (es) | Compuestos de benzimidazol que son antagonistas de receptor de vitronectina | |
| PE20212302A1 (es) | Inhibidores de apol1 y sus metodos de uso | |
| AR037562A2 (es) | Derivados de indolinona como moduladores de tirosina quinasas (pkt) | |
| ECSP034932A (es) | Derivados de tetrahidroquinolina | |
| AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
| CO4950611A1 (es) | Derivados de 9-desoxo-9a-aza-9a-homoeritromicina ac-4 sustituidos | |
| MX9700883A (es) | Derivados sustituidos de la quinazolina. | |
| CO5630036A2 (es) | Nuevos derivados indol con afinidad por el receptor 5-ht6 | |
| CO5261616A1 (es) | Inhibidores no peptidicos de la union celular dependientes de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias | |
| NZ336302A (en) | Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia | |
| CO5271658A1 (es) | Antagonistas del factor liberador de corticotropina | |
| CA2288705A1 (en) | Use of quinazoline compounds for the treatment of polycystic kidney disease | |
| SE0104332D0 (sv) | Therapeutic agents | |
| PA8431301A1 (es) | Inhibidores de metaloproteinasas, composiciones farmaceuticas que los contienen y sus usos farmaceuticos y los metodos e intermedios utiles para su preparacion | |
| DK0874824T3 (da) | Trisubstituerede phenylderivater nyttige som PDE IV inhibitorer | |
| MXPA04000532A (es) | Derivados de 8-metoxi-(1,2,4)-triazolo(1,5-a)piridina y su uso como ligandos receptores de adenosina. | |
| AR030189A1 (es) | Compuesto de benzotiazol, uso del mismo para preparar una composicion farmaceutica y dicha composicion farmaceutica | |
| AR004735A1 (es) | Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento. | |
| EA200000400A1 (ru) | Галогензамещенные тетрациклические производные тетрагидрофурана | |
| AR037008A1 (es) | El uso del antagonista del receptor nk-1 para la elaboracion de un medicamento para el tratamiento y/o prevencion de lesiones cerebrales, espinales o neuronales y una composicion farmaceutica que comprende uno o mas de dicho antagonista. | |
| YU18999A (sh) | Supstituisani tricikli | |
| CO5170529A1 (es) | Derivados de 5-(fenil sustituido)-2-piperazinil-pirimidin-(3,5- bistrifluoro-metil-bencil)-metil-amida | |
| AR036905A1 (es) | Derivados del 3-azabiciclo[3.1.0]hexano, composiciones farmaceuticas que los contienen, su uso en un metodo para tratar un trastorno o afeccion en un mamifero, e intermediarios utiles para su sintesis | |
| BR0215017A (pt) | Lactamas como antagonistas da taquiquinina | |
| AR042002A1 (es) | Benzoxazinonas sustituidas, proceso de obtencion y usos para tratamiento de enfermedades del sistema nervioso central. |